Cargando…
Anti‐CD20 therapeutic options in immune‐mediated thrombotic thrombocytopenic purpura
Immunosuppression with rituximab in immune‐mediated thrombotic thrombocytopenic purpura helps decrease production of autoantibody mediating ADAMTS13 clearance from circulation. Failure to respond to rituximab in a satisfactory way or made difficult by adverse events to the medication does not repres...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540546/ https://www.ncbi.nlm.nih.gov/pubmed/35472189 http://dx.doi.org/10.1111/bjh.18215 |